All In Biotech

Drug Trial Radar · NCT06321562

Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

A First-In-Human, Open-Label, Dose Escalating, Non-Randomized Study to Assess the Safety and Tolerability of a New Timolol Sustained Release Intraocular Implant (TimoD) in Subjects With Primary Open Angle Glaucoma With Pseudophakia

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Mar 1, 2023

Primary completion

Jun 26, 2025

Study completion Jun 26, 2025

Sponsor

Lead sponsor
EyeD PharmaIndustry
Sponsor type
Industry
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia (currently present or to be performed during the concomitant implantation surgery in subjects with age-related cataract eligible to intra-capsular IOL placement). The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it. The study will also check: * how safely the implant is placed in and removed from the eye and how the body responds to the procedure, * how safe different doses of timolol are and how the body handles taking it, * the amount of Timolol released in the bloodstream, * if there is any positive effect on the pressure inside the eye.

Conditions

  • Primary Open-angle Glaucoma

Interventions

  • TimoD implantDrug

    Consists of 1 TimoD implant administration in the study eye

  • Injector systemDevice

    This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and proportion of participants experiencing one or more serious adverse events (SAEs)Time frame: From screening visit (up to Day -41) to end of study (Week 108)
  2. Number and proportion of participants experiencing one or more treatment-emergent adverse events (TEAEs) overall and by dose groupTime frame: From screening visit (up to Day -41) to end of study (Week 108)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Breyer, Kaymak & Klabe Augenchirurgie

    Düsseldorf, Germany

  • Universitäts-Augenklinik Heidelberg

    Heidelberg, Germany

  • Universitätsaugenklinik Magdeburg

    Magdeburg, Germany

  • Augenklinik Sulzbach

    Sulzbach, Germany

  • Universitäts-Augenklinik Tübingen

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.